Why Antibiotic Treatment May Fail in Tilapia Streptococcosis

Continued mortality during antibiotic treatment can have several explanations beyond the choice of antimicrobial. 

With Streptococcus agalactiae infection, treatment failure can involve systemic infection, persistence of bacteria within host cells, and antimicrobial resistance. Understanding these factors is important when evaluating an unfavourable treatment response rather than attributing continued mortality to drug selection alone. 

Streptococcosis can become a systemic infection 

S. agalactiae does not remain confined to one site. The bacteria can enter the bloodstream through areas of local necrosis and proliferate within macrophages, particularly in the spleen. Bacteremia can then facilitate dissemination to other tissues^[1],[2]. 

Bacterial colonies and exotoxins have been identified in lesions involving the liver, spleen, kidney and brain^[1],[3],[4]. 

This systemic distribution is clinically relevant when mortality persists. A fish may have disease affecting several organs rather than a localised bacterial process. 

The intracellular location of bacteria matters^[1] 

One important feature of S. agalactiae infection is its interaction with macrophages. 

In O. niloticus, bacterial copies were reported to peak at 24 hours after infection. During bloodstream infection, bacteria may occur freely in blood, be phagocytised by phagocytes or red blood cells, or adhere to vessel walls. 

The bacteria can also survive intracellularly within macrophages. This has been described in relation to a “Trojan horse” mechanism, through which infected macrophages may facilitate disruption of the blood–brain barrier and contribute to meningitis in tilapia. 

For veterinarians, this helps explain why the disease can involve neurological tissues as well as multiple internal organs. 

Resistance can change the treatment equation^[1] 

Antimicrobial resistance is another important consideration in S. agalactiae management. 

The available findings describe differences in antimicrobial susceptibility among isolates. One reported comparison found that isolates from diseased tilapia showed higher resistance to certain antibiotics than isolates from other sources, with resistance to erythromycin, oxytetracycline, sulfamethoxazole, doxycycline and gentamicin reported among the tested isolates. 

Resistance patterns can also vary between isolates and locations. Therefore, continued mortality during treatment should not automatically be interpreted as evidence that the disease is unrelated to S. agalactiae. 

Why repeated treatment may not solve the problem^[1] 

Another challenge is that disease severity depends on multiple interacting factors. Bacterial strain and virulence, bacterial concentration, fish species, individual host response, infection route, stocking density, environmental fluctuations, management practices and coinfections can influence the outcome. 

Environmental conditions can also increase vulnerability. High water temperature, low dissolved oxygen, high stocking density and elevated ammonia have been associated with streptococcal disease. 

If these conditions remain unchanged, mortality may continue even when antimicrobial intervention is being attempted. 

What should persistent mortality prompt? 

When mortality continues during treatment, the response should involve reassessment rather than automatically escalating or repeating antimicrobial use. 

The diagnosis should be confirmed through appropriate laboratory identification, while the veterinarian should also consider antimicrobial susceptibility and the environmental and management conditions surrounding the outbreak. 

The key point: Treatment failure in tilapia streptococcosis cannot be attributed to antimicrobial choice alone. Systemic disease, intracellular bacterial survival, antimicrobial resistance and ongoing farm-level stressors can all contribute to an unfavourable clinical outcome. A treatment response should therefore be interpreted alongside diagnostic and farm-level findings.

References:

1. Abdallah ES, Metwally WG, Abdel-Rahman MA, Albano M, Mahmoud MM. Streptococcus agalactiae infection in Nile tilapia (Oreochromis niloticus): A review. Biology. 2024 Nov 11;13(11):914. https://www.mdpi.com/2079-7737/13/11/914\
2. Ferrari NA, Favero LM, Facimoto CT, Dall Agnol AM, Gaeta ML, de Oliveira TE, Gonçalves DD, Lopera-Barrero NM, Pereira UD, Di Santis GW. Clinical and histopathological evolution of acute intraperitoneal infection by Streptococcus agalactiae serotypes Ib and III in nile tilapia. Fishes. 2024 Jul 13;9(7):279. https://www.mdpi.com/2410-3888/9/7/279
3. Suanyuk N, Kong F, Ko D, Gilbert GL, Supamattaya K. Occurrence of rare genotypes of Streptococcus agalactiae in cultured red tilapia Oreochromis sp. and Nile tilapia O. niloticus in Thailand—relationship to human isolates?. Aquaculture. 2008 Nov 1;284(1-4):35-40. https://www.academia.edu/download/69921347/j.aquaculture.2008.07.03420210919-21438-1g1yay1.pdf
4. Chen C, Chao C, Bowser PR. Comparative histopathology of Streptococcus iniae and Streptococcus agalactiae-infected tilapia. Bulletin-European Association of Fish Pathologists. 2007 Jan 1;27(1):2. https://www.eafp.org/download/2007-Volume27/Issue%201/27_002.pdf